Use of Substance P antagonists to regulate the skin immune function
Use of Substance P antagonists to regulate the skin immune function
批准号:
8486370
负责人:
Adriana T Larregina
金额:
$34.89万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2014-06-30
关键词:
AddressAffinityAlcohol or Other Drugs useAntigen-Presenting CellsAntigensBindingC FiberCD14 geneCD8B1 geneCell physiologyCellsCellular ImmunityClinical TrialsComplexContact hypersensitivityCutaneousCutaneous AdministrationCytotoxic T-LymphocytesDendritic CellsDermalDevelopmentDinitrochlorobenzeneDiseaseExposure toGenerationsHaptensHealthHomingHumanImmuneImmune System DiseasesImmune responseImmune systemInflammationInflammation MediatorsInflammatoryLangerhans cellLymphoid TissueMediatingModelingMusNatural Killer CellsNervous system structureNeuropeptidesOrganPenetrationPeripheralPhasePopulationPre-Clinical ModelPreventionProteinsRecurrenceRegulationResearchResolutionRoleSensorySignal TransductionSkinSubstance PSubstance P ReceptorT cell responseT memory cellT-LymphocyteTNF geneTestingTranslationsimmune functionkeratinocytelymph nodesmast cellmigrationmodel designpreventprototyperesponseskin disordersocioeconomicstherapy development
中文摘要
描述(由申请人提供):复发性炎症性疾病是具有高度社会经济影响的常见皮肤疾病。接触性超敏反应(CHS)是一种典型的复发性皮肤炎性疾病,它依赖于免疫系统和神经系统的相互作用。CHS需要活化识别皮肤细胞中存在的半抗原的CD 4+和CD 8+效应T细胞。CHS中效应T细胞的活化需要免疫刺激性皮肤树突状细胞DC(sDC),包括表皮朗格汉斯细胞(LC)和真皮DC(DDC),其将半抗原转运至皮肤引流淋巴结(sDLN)并活化初始T细胞。因此,抑制免疫刺激性DC将是预防和治疗皮肤免疫疾病的理想方法。然而,由于皮肤免疫系统的复杂调节,靶向刺激性sDC的疗法的开发一直极其困难。免疫刺激性DC的产生需要在DC-抗原(Ag)/半抗原相互作用时的促炎微环境。这种炎症微环境由皮肤暴露于Ag/半抗原后释放的促炎神经肽启动。P物质(SP)是原型促炎神经肽,其通过促进免疫细胞的活化、增殖和存活而有利于细胞免疫。在皮肤中,SP主要由感觉C-纤维分泌,所述感觉C-纤维将细胞与免疫功能例如LC、肥大细胞(MC)和角质形成细胞互连。SP通过结合神经激肽1受体(NK 1 R)发挥其免疫刺激功能,我们已经描述了sDC表达功能性NK 1 R,并通过诱导Th 1和CTL效应子对蛋白Ag的免疫应答来应答NK 1 R激动性结合。然而,在皮肤CHS的起始和复发期间,缺乏解决局部分泌的SP对sDC的成熟和T细胞免疫刺激功能的作用的相关研究。我们假设:“在皮肤Ag/半抗原穿透的瞬间,SP通过NK 1 R的促炎信号传导促进免疫刺激性sDC及其前体的活化,导致皮肤免疫疾病的开始、持续和复发,这可以通过局部施用NK 1 R拮抗剂来限制”。为了验证我们的假设,我们提出了以下具体目标:具体目标1:分析SP在CHS致敏阶段诱导免疫刺激性sDC的机制。具体目标二:分析SP在CHS的致敏、诱导和消退过程中,由sDC刺激的T细胞应答中的作用和机制。具体目标3:分析使用特异性NK 1 R拮抗剂局部给药通过下调sDC及其前体的T细胞刺激功能来抑制CHS的可能性。
英文摘要
DESCRIPTION (provided by applicant): Recurrent inflammatory diseases are common skin disorders with high socioeconomic impact. Contact hypersensitivity (CHS) is the prototype recurrent skin inflammatory disease that relays on the interaction of the immune and nervous systems. CHS requires activation of CD4+ and CD8+ effector T cells recognizing haptens present in skin cells. Activation of effector T cells, in CHS requires immunostimulatory skin dendritic cells DCs (sDCs) including epidermal Langerhans cells (LCs) and dermal DCs (DDCs) that transport haptens to skin draining lymph nodes (sDLNs) and activate naive T cells. Thus, inhibition of immunostimulatory DCs would be ideal for the prevention and treatment of skin immune diseases. However, the development of therapies targeting stimulatory sDCs has been extremely difficult due to the complex regulation of the skin immune system. The generation of immunostimulatory DCs requires a pro- inflammatory microenvironment at the moment of DC-antigen (Ag) /hapten interaction. This inflammatory microenvironment is initiated by pro-inflammatory neuropeptides released after skin exposure to Ag/haptens. Substance-P (SP) is the prototype pro-inflammatory neuropeptide which favors cellular immunity by promoting the activation, proliferation and survival of immune cells. In the skin, SP is mainly secreted by sensory C-fibers that interconnect cells with immune function such as LCs, mast cells (MCs), and keratinocytes. SP exerts its immunostimulatory functions by binding the neurokinin 1 receptor (NK1R).We have described that sDCs express functional NK1R and respond to NK1R agonistic binding by inducing Th1 and CTL effector immune responses to protein Ag. Nevertheless, relevant studies addressing the role of locally secreted SP, on the maturation and T cell immunostimulatory function of sDCs during the initiation and recurrence of skin CHS are lacking. We hypothesize that: "Pro-inflammatory signaling by SP through the NK1R, at the moment of skin Ag/hapten penetration, promotes the activation of immunostimulatory sDCs and their precursors resulting in the initiation, persistence and recurrence of skin immune diseases which can be limited by local administration of NK1R antagonists". To test our hypothesis we propose the following specific aims: Specific Aim 1: To analyze the mechanisms employed by SP to induce immunostimulatory sDCs during the sensitization phase of CHS. Specific Aim 2: To analyze the role and mechanisms employed by SP in T cell responses, stimulated by sDCs during sensitization, elicitation and resolution of CHS. Specific Aim 3: To analyze, the possibility of using local administration of specific NK1R antagonists to suppress CHS by down-regulating the T cell-stimulatory function of sDCs and their precursors.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1007/978-1-4939-1158-5_7
发表时间:
2014
期刊:
Methods in molecular biology
影响因子:
--
作者:
[Angela Montecalvo;A. Larregina;A. Morelli]
通讯作者:
Angela Montecalvo;A. Larregina;A. Morelli
DOI:
10.1016/j.jaci.2014.07.036
发表时间:
2015-04
期刊:
The Journal of allergy and clinical immunology
影响因子:
--
作者:
[Sumpter TL, Ho CH, Pleet AR, Tkacheva OA, Shufesky WJ, Rojas-Canales DM, Morelli AE, Larregina AT]
通讯作者:
Larregina AT
DOI:
10.1007/978-1-62703-453-1_3
发表时间:
2013-01-01
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Montecalvo, Angela, Larregina, Adriana T, Morelli, Adrian E]
通讯作者:
Morelli, Adrian E
Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases.
神经激肽-1 受体在皮肤慢性炎症性疾病的引发和维持中的作用。
DOI:
10.1007/s12026-011-8219-9
发表时间:
2011
期刊:
Immunologic research
影响因子:
4.4
作者:
[Divito,SherrieJ, Morelli,AdrianE, Larregina,AdrianaT]
通讯作者:
Larregina,AdrianaT
DOI:
10.1002/art.37706
发表时间:
2013-01
期刊:
ARTHRITIS AND RHEUMATISM
影响因子:
--
作者:
[Fuschiotti, Patrizia, Larregina, Adriana T., Ho, Johnan, Feghali-Bostwick, Carol, Medsger, Thomas A., Jr.]
通讯作者:
Medsger, Thomas A., Jr.
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis
-
批准号:10581825
-
项目类别:
-
资助金额:$59.56万
-
财政年份:2022
-
负责人:Adriana T Larregina
-
依托单位:
Role of neurokinin 1 receptor signaling in keratinocytes in allergic contact dermatitis
-
批准号:10707217
-
项目类别:
-
资助金额:$59.56万
-
财政年份:2022
-
负责人:Adriana T Larregina
-
依托单位:
Use of Substance P antagonists to regulate the skin immune function
-
批准号:8289511
-
项目类别:
-
资助金额:$37.12万
-
财政年份:2009
-
负责人:Adriana T Larregina
-
依托单位:
Use of Substance P antagonists to regulate the skin immune function
-
批准号:7726347
-
项目类别:
-
资助金额:$37.43万
-
财政年份:2009
-
负责人:Adriana T Larregina
-
依托单位:
Use of Substance P antagonists to regulate the skin immune function
-
批准号:8078942
-
项目类别:
-
资助金额:$37.12万
-
财政年份:2009
-
负责人:Adriana T Larregina
-
依托单位:
Use of Substance P antagonists to regulate the skin immune function
-
批准号:7872833
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:Adriana T Larregina
-
依托单位:
Use of Adjuvants to Improve Skin Genetic Immunizations
-
批准号:7409594
-
项目类别:
-
资助金额:$25.63万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
Immune role of CD14+ & CD14- human skin dendritic cells
-
批准号:6877157
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
Immune role of CD14+ & CD14- human skin dendritic cells
-
批准号:6712216
-
项目类别:
-
资助金额:$22.29万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
Use of Adjuvants to Improve Skin Genetic Immunizations
-
批准号:6858587
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
Use of Adjuvants to Improve Skin Genetic Immunizations
-
批准号:7008842
-
项目类别:
-
资助金额:$26.41万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
Use of Adjuvants to Improve Skin Genetic Immunizations
-
批准号:7189825
-
项目类别:
-
资助金额:$25.64万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
Use of Adjuvants to Improve Skin Genetic Immunizations
-
批准号:6721071
-
项目类别:
-
资助金额:$26.35万
-
财政年份:2004
-
负责人:Adriana T Larregina
-
依托单位:
海外基金